Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
03 Maio 2023 - 8:01AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that management will
present and participate during the following conferences in
May.
- JMP Securities 2023 Life Sciences Conference in New York, NY
- RBC Annual Healthcare Conference in New York, NY
- May 16 at 10:00 a.m. E.T.
Links to the events can be accessed on the Investors and Media
page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations. A replay of the
webcasts will be available approximately two hours after the
completion of the events and will be archived for up to 90
days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company’s commercial product, ZTALMY® (ganaxolone)
oral suspension CV, has been approved by the U.S. FDA for the
treatment of seizures associated with CDKL5 deficiency disorder in
patients two years of age and older. The potential of ganaxolone is
also being studied in other rare seizure disorders, including in
Phase 3 trials in tuberous sclerosis complex and refractory status
epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor
modulator that acts on a well-characterized target in the brain
known to have anti-seizure effects. It is being developed in IV and
oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005050/en/
Company Contact Sasha Damouni Ellis Senior Vice
President, Corporate Affairs & Investor Relations Marinus
Pharmaceuticals, Inc. sdamouni@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
